NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (the “Company”) (NYSE Alternext US: PRW) today has filed a registration statement with the Securities and Exchange Commission for its previously announced rights offering in which it plans to distribute, at no charge to its existing holders of the Company’s common stock on the record date, non-transferable subscription rights to purchase shares of its common stock and Series C warrants. The Company expects to use the proceeds from the rights offering to complete the submission to the U.S. Food and Drug Administration of the Company’s new drug application for DAVANAT®, as well as for general working capital.
